Prices are updated after-hours
  Health Technology 2021 - 01 - 05

nasdaq:HSKA Heska Corporation

HSKA | $119.99 0.0% 390K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (2.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (87.26% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,309,541,342
http://www.heska.com
 Sec Filling | Patents | 386 employees


(US) Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals. The Core Companion Animal Health segment includes point of care diagnostic laboratory instruments and supplies, imaging instruments, software, and services as well as single use diagnostic and other tests, pharmaceuticals, and vaccines. The Other Vaccines & Pharmaceuticals segment focuses on private label vaccine and pharmaceutical production, primarily for cattle, but also for equine, porcine, avian, feline, and canine. Heska was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.
vaccine   animals   diagnostics   veterinary  

add to watch list Paper trade email alert is off

nasdaq:HSTO Histogen Inc.

HSTO 4 d | $0.5 67.46% 530 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (28.2% 1m) (-47.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-68.82% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,135,880
http://www.histogen.com
 Sec Filling | Patents | 6 employees


Histogen, Inc. engages in the development of patented, innovative technologies that replace and regenerate tissues in the body for the aesthetic and therapeutic markets. Its technology is based on the discovery that growing fibroblast cells under simulated embryonic conditions induces them to become multipotent stem cells. The environment created by its proprietary process mimics the conditions within the womb very low oxygen and suspension. When cultured under these conditions, the induced multipotent stem cells generate biological materials that stimulate a patient’s own stem cells to activate and regenerate tissue. This results in potential therapeutic benefits in multiple treatment settings, including skin care, orthopedic indications such as cartilage formation and spinal disc repair, wound healing and dermal fillers. The company was founded on July 13, 2005 by Steven J. Mento and is headquartered in San Diego, CA.
dermatitis   cartilage   skin   stem cell   t-cell   aesthetic   treatment   ceiling  

add to watch list Paper trade email alert is off

amex:AGE AgeX Therapeutics, Inc.

AGE A | $11.1 0.0% 3.8K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-11.9% 1m) (1594.7% 1y) (0.0% 2d) (2.2% 3d) (-11.9% 7d) (-14.98% volume)
Earnings Calendar:
Market Cap: $ 27,757,370
http://www.agexinc.com
 Sec Filling | Patents | 17 employees


(US) AgeX Therapeutics, Inc. operates as a biotechnology company. The firm focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its technology platforms include PureStem, UniverCyte, iTR and HyStem. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.
msa  

add to watch list Paper trade email alert is off

nasdaq:BLCM Bellicum Pharmaceuticals, Inc.

BLCM | $0.0748 381.28% 6.1K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-77.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
 Sec Filling | Patents | 107 employees


(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
cancer   immunotherapy  

add to watch list Paper trade email alert is off

nasdaq:BBI Brickell Biotech, Inc.

BBI | $2.12 16.04% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
 Sec Filling | Patents | 15 employees


(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
dermatitis   skin   t-cell   treatment   ceiling  

add to watch list Paper trade email alert is off

nasdaq:CMPI Checkmate Pharmaceuticals, Inc.

CMPI | $10.5 0.0% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
 Sec Filling | Patents | 22 employees


Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.
cancer  

add to watch list Paper trade email alert is off

nasdaq:HTGM HTG Molecular Diagnostics, Inc.

HTGM | $0.48 -20.0% -26.08% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-80.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-46.41% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 1,062,832
http://www.htgmolecular.com
 Sec Filling | Patents | 112 employees


HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It offers instruments, reagents and services for molecular profiling applications. The firm serves biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
molecular diagnostics   multiplexing   diagnostics   profitable  

add to watch list Paper trade email alert is off

nasdaq:IMGN ImmunoGen, Inc.

IMGN | News | $31.23 0.03% 49M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (673.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
 Sec Filling | Patents | 75 employees


(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.
cancer   antibody  

add to watch list Paper trade email alert is off

nasdaq:ICPT Intercept Pharmaceuticals, Inc.

ICPT | $19.0 -0.05% 4M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.1% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 794,693,354
http://www.interceptpharma.com
 Sec Filling | Patents | 583 employees


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
sclerosis   liver   liver disease   treatment  

add to watch list Paper trade email alert is off

nasdaq:IIN IntriCon Corporation

IIN | $24.24 0.04% 0.04% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.43% volume)
Earnings Calendar: 2022-08-08
Market Cap:
http://www.intricon.com
 Sec Filling | Patents | 780 employees


Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-End Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets. The Hearing Health Direct-To-End Consumer segment provides advanced hearing products such as ultra-miniature volume controls and trimmers, custom amplifiers, and custom, completed hearing instruments. The company was founded in 1930 and is headquartered in Arden Hills, MN.
audio  

add to watch list Paper trade email alert is off

nasdaq:NVIV InVivo Therapeutics Holdings Corp.

NVIV | $0.3207 -25.16% 1.9M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-58.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-98.2% volume)
Earnings Calendar:
Market Cap: $ 995,917
http://www.invivotherapeutics.com
 Sec Filling | Patents | 6 employees


(US) Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.
spinal cord   msa   treatment  

add to watch list Paper trade email alert is off

nasdaq:ISEE IVERIC bio, Inc.

ISEE | $39.95 0.38% 0.38% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.2% 1m) (25.7% 1y) (0.2% 2d) (0.6% 3d) (0.0% 7d) (-41.69% volume)
Earnings Calendar: 2023-08-01
Market Cap: $ 5,504,420,783
http://www.ivericbio.com
 Sec Filling | Patents | 38 employees


IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
gene therapies  

add to watch list Paper trade email alert is off

nasdaq:EPZM Epizyme, Inc.

EPZM | $1.47 -1.34% 0.0% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-1.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2022-08-08
Market Cap: $ 247,496,185
http://www.epizyme.com
 Sec Filling | Patents | 203 employees


(US) Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
cancer   ovarian cancer   t-cell   lungs   genetic   leukemia   ceiling  

Drugs
TAZVERIK (tazemetostat)

add to watch list Paper trade email alert is off

nasdaq:LJPC La Jolla Pharmaceutical Company

LJPC | $6.22 0.0% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-0.2% 1m) (0.0% 1y) (0.0% 2d) (0.8% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 155,107,412
http://www.lajollapharmaceutical.com
 Sec Filling | Patents | 91 employees


(US) La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.
hormone   msa   treatment  

Drugs
Giapreza (angiotensin II)

add to watch list Paper trade email alert is off

nasdaq:BXRX Baudax Bio, Inc.

BXRX | $0.1864 -54.35% 330K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-90.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.34% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 1,710,656
http://www.baudaxbio.com
 Sec Filling | Patents | 25 employees


Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.


Drugs
Anjeso (meloxicam)

add to watch list Paper trade email alert is off

nasdaq:SPNE SeaSpine Holdings Corporation

SPNE | $9.54 8.29% -1.99% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (314.37% volume)
Earnings Calendar: 2023-03-10
Market Cap: $ 354,914,712
http://www.seaspine.com
 Sec Filling | Patents | 386 employees


(US) SeaSpine Holdings Corp. is a medical technology company, which engages in the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It products include thoracolumbar hardware, cervical hardware, orthobiologics, and spine pure strip. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.
treatment  

add to watch list Paper trade email alert is off

nasdaq:EYES Second Sight Medical Products, Inc.

EYES | $4.14 -0.24% 3.14% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap:
http://www.secondsight.com
 Sec Filling | Patents | 112 employees


Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
china   prosthetics  

add to watch list Paper trade email alert is off

nasdaq:TMDI Titan Medical Inc.

TMDI | News | $0.14 -26.32% -35.52% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-25.3% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 15,673,600
http://www.titanmedicalinc.com
 Sec Filling | Patents | 10 employees


(CA) Titan Medical, Inc. engages in the research and development of SPORT Surgical System, a computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS) comprising single-port robotic surgical system. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.
computational  

add to watch list Paper trade email alert is off

nasdaq:TPTX Turning Point Therapeutics, Inc.

TPTX | $76.01 -0.03% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,806,145,795
http://www.tptherapeutics.com
 Sec Filling | Patents | 95 employees


Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.
cancer  

add to watch list Paper trade email alert is off

nasdaq:TYME Tyme Technologies, Inc.

TYME | $0.3107 -8.21% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (8.1% 2d) (18.4% 3d) (0.0% 7d) (-9.91% volume)
Earnings Calendar:
Market Cap: $ 53,504,682
http://www.tymeinc.com
 Sec Filling | Patents | 18 employees


(United States) Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.
cancer   t-cell   ceiling  

add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
89% 11%

Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M twitter stocktwits trandingview |

AGBA | $2.355 88.4% 34M twitter stocktwits trandingview |
Finance
EDBL | News | $6.94 84.57% 1.4M twitter stocktwits trandingview |

CZOO | $8.77 75.75% 11M twitter stocktwits trandingview |

VNRX | $0.84 40.0% 2.6M twitter stocktwits trandingview |
Health Technology
OPRT | News | $3.01 33.78% 6.8M twitter stocktwits trandingview |
Finance
MLEC | $1.81 29.29% 2M twitter stocktwits trandingview |
n/a
CMAX | $4.12 28.35% 65K twitter stocktwits trandingview |
Manufacturing
MTC | $2.0 28.21% 1.7M twitter stocktwits trandingview |
Technology Services
PEGY | $0.0586 27.95% 130M twitter stocktwits trandingview |
Manufacturing
Last 48 Hours Insiders Buying
TPL P 3 | $585.25 -0.1% 4.7K twitter stocktwits trandingview |
Miscellaneous
 | 15:00
ETST P 79000 | $0.065 110K twitter stocktwits trandingview |
Manufacturing
 | 11:30
MCFT P 26039 | $22.0 2.33% 29K twitter stocktwits trandingview |
Consumer Durables
 | 00:00
YORW P 29 | $35.6 0.51% 11K twitter stocktwits trandingview |
Utilities
 | 19:01
VUZI P 14500 | $1.34 -0.74% 84K twitter stocktwits trandingview |
Electronic Technology
 | 17:00
BANF P 256 | $92.43 1.26% 5.7K twitter stocktwits trandingview |
Finance
 | 15:30
RMCF | $3.57 170 twitter stocktwits trandingview |
Consumer Non-Durables
 | 20:10
12 months watchlist earnings calendar